Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

Caussy, Cyrielle; Alquiraish, Mosab H.; Nguyen, Phirum; Hernandez, Carolyn; Cepin, Sandra; Fortney, Lynda; Ajmera, Veeral; Bettencourt, Ricki; Collier, Summer; Hooker, Jonathan; Sy, Ethan; Rizo, Emily; Richards, Lisa; Sirlin, Claude B.; Loomba, Rohit

doi:10.1002/hep.29639

Cited by 289 publications

(285 citation statements)

References 57 publications

Supporting

Mentioning

272

Contrasting

Unclassified

Order By: Relevance

“…In a sensitivity analysis, considering the value of 288 dB/m as recently proposed for the diagnosis of NAFLD, the prevalence of fatty liver was lower, ie, 27.2%. On multivariate analyses we confirmed age ≥50 years (OR: 1.73, C.I.…”

Section: Resultsmentioning

confidence: 96%

“…Caussy et al recently found that CAP can lead to a significant rate of misclassification for fatty liver. They also proposed a threshold of 288 dB/m for the diagnosis of steatosis by using as reference method magnetic resonance imaging and not the histology from biopsy specimens . Using the Caussy reference value for CAP, the prevalence of fatty liver in our population was about 27%.…”

Section: Discussionmentioning

confidence: 94%

“…In a sensitivity analysis, considering the value of 288 dB/m as recently proposed for the diagnosis of NAFLD, the prevalence of liver stiffness values suggestive of advanced fibrosis in patients with NAFLD was 7.9%, high ALT levels (OR: 3.85, C.I. 1.24‐11.9, P = .02), IFG/Diabetes (OR: 4.70, C.I.…”

Section: Resultsmentioning

confidence: 99%

“…In the setting of a Mediterranean general population, we confirmed the PNPLA3 variant as an independent risk factor for NAFLD, its effect being, however, modest, and more evident in individuals with obesity and in those without obesity but with other metabolic risk factors. When using a high CAP value (288 dB/m) for the diagnosis of steatosis, no association between NAFLD and PNPLA3 gene variant was found. All in all, these data suggest that in a general population, the real effect of PNPLA3 on steatosis is not dominant, with metabolic factors being more relevant.…”

Section: Discussionmentioning

confidence: 96%

See 3 more Smart Citations

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population

Petta

Marco

Pipitone

et al. 2018

Liver International

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 96%

See 2 more Smart Citations

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population

Petta

Marco

Pipitone

et al. 2018

Liver International

View full text Add to dashboard Cite

show abstract

“…Overall literature suggests that CAP measurement correlates with the histological severity of hepatic steatosis . Furthermore, in patients at risk, CAP measurement, when technically reproducible, has a good diagnostic accuracy to diagnose NAFLD, when MRI‐PDFF is used as the reference . Given the wide availability and the low costs, future studies are warranted to examine the utility of hepatic fat content monitoring by CAP measurement in clinical practice.…”

Section: Imaging Studiesmentioning

confidence: 99%

Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease

Pelusi

Valenti

2018

Liver International

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of advanced liver disease in Western countries. NAFLD is defined in the presence of increased hepatic fat content, which is mainly stored under the form of neutral lipids within intracellular droplets and is not explained by at risk alcohol intake. In order to understand the pathogenesis, monitor the progression and find novel treatments for this condition, previous research efforts mainly addressed the role of inflammation. However, very recent data seem to suggest that hepatic lipid accumulation may be involved in NAFLD pathogenesis by driving secondary inflammation and fibrosis progression. Here, we will briefly review the novel results derived from natural history, genetics, imaging studies and therapeutic trials that support the notion that hepatic fat accumulation may represent a major clinical outcome and therapeutic target for NAFLD. Indeed, prospective and genetic data are consistent with hepatic fat being a driver of NAFLD progression. Furthermore, new technologies will render possible to monitor hepatic fat content without the need of invasive assessment, thereby allowing to identify patients at higher risk, and to monitor the response to drugs that act by decreasing hepatic lipid accumulation.

show abstract

Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials

et al. 2018

Self Cite

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration-approved therapies for treating NASH. A major barrier for drug development in NASH is that treatment response assessment continues to require liver biopsy, which is invasive and interpreted subjectively. Therefore, there is a major unmet need for developing noninvasive, objective, and quantitative biomarkers for diagnosis and assessment of treatment response. Emerging data support the use of magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) as a noninvasive, quantitative, and accurate measure of liver fat content to assess treatment response in early-phase NASH trials. In this review, we discuss the role and utility, including potential sample size reduction, of MRI-PDFF as a quantitative and noninvasive imaging-based biomarker in early-phase NASH trials. Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide. NAFLD can be broadly classified into two categories: nonalcoholic fatty liver, which has a minimal risk of progression to cirrhosis, and nonalcoholic steatohepatitis (NASH), the more progressive form of NAFLD, which has a significantly increased risk of progression to cirrhosis. Over the past two decades, NASH-related cirrhosis has become the second leading indication for liver transplantation in the United States. For these reasons, pharmacological therapy for NASH is needed urgently. Despite intensive investigations, there are currently no therapies for treating NASH that have been approved by the United States Food and Drug Administration..

show abstract

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

Cited by 289 publications

References 57 publications

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population

Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease

Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials

Contact Info

Product

Resources

About